Compare BDSX & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDSX | JCE |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.5M | 269.8M |
| IPO Year | 2020 | N/A |
| Metric | BDSX | JCE |
|---|---|---|
| Price | $6.85 | $15.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 66.8K | 49.7K |
| Earning Date | 11-03-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,173,000.00 | N/A |
| Revenue This Year | $20.75 | N/A |
| Revenue Next Year | $25.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.29 | N/A |
| 52 Week Low | $3.44 | $11.64 |
| 52 Week High | $31.20 | $14.28 |
| Indicator | BDSX | JCE |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 55.76 |
| Support Level | $6.56 | $15.47 |
| Resistance Level | $7.03 | $16.12 |
| Average True Range (ATR) | 0.57 | 0.17 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 26.44 | 76.47 |
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.